(S)-α-amino-N-(4-pyridyl)benzene propanamide | 88932-74-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-α-amino-N-(4-pyridyl)benzene propanamide
• 英文别名: (S)-2-amino-3-phenyl-N-(pyridin-4-yl)propanamide；4-l-Phenylalanylamino-pyridine；(2S)-2-amino-3-phenyl-N-pyridin-4-ylpropanamide
• CAS: 88932-74-5
• 化学式: C₁₄H₁₅N₃O
• mdl: MFCD13245064
• 分子量: 241.293
• InChiKey: FVNFCSADMHUNIG-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-α-amino-N-(4-pyridyl)benzene propanamide 在 N-甲基吗啉 、 盐酸 、 氯甲酸异丁酯 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 ((S)-1-(4-Hydroxy-benzyl)-2-oxo-2-{(S)-2-[(S)-2-phenyl-1-(pyridin-4-ylcarbamoyl)-ethylcarbamoyl]-pyrrolidin-1-yl}-ethyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Development of Potent Bifunctional Endomorphin-2 Analogues with Mixed μ-/δ-Opioid Agonist and δ-Opioid Antagonist Properties

  摘要：

  The C terminus of endomorphin-2 (EM-2) analogues (Tyr-Pro-Phe-NH-X) was modified with aromatic, heteroaromatic, or aliphatic groups (X = phenethyl,benzyl, phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, tert-butyl, cyclohexyl, or adamantyl; 3-18) to study their effect on opioid activity. Only 9 (1-naphthyl), 11 (5-quinolyl), 16 (cyclohexyl), and 18 (2-adamantyl) exhibited mu-opioid receptor affinity in the nanomolar range (K-i = 2.41-6.59 nM), which, however, was 3- to 10-fold less than the parent peptide. Replacement of Tyr(1) by Dmt (2',6'-dimethyl-L-tyrosine) (19-32) exerted profound effects: (i) acquisition of high mu-opioid receptor affinity (K-i = 0.11-0.52 nM) except 23 (Ph); (ii) presence of potent functional mu-opioid receptor agonism (IC50 < 1 nM) for 19 ([Dmt(1)]EM-2), 27 (1-naphthyl), 29 (5-quinolyl), and 32 (5-isolquinolyl); (iii) association of weak delta-opioid antagonist activity (pA(2) = 5.41-7.18) except 19 ([Dmt(1)]EM-2), 20 (H), 27 (1-naphthyl), and in particular 29 (5-quinolyl) with its potent delta-agonism (IC50 = 0.62 nM, pA(2) = 5.88); (iv) production of antinociception after ic administration of 32 (5-isoquinolyl) in mice, a bioactivity absent in the corresponding Tyr(1) analogue (14); and (v) preferential cis orientation (cis/trans = 3:2 to 7:3) at the Dmt-Pro amide bond, in contrast to the Tyr-Pro amide trans orientation (cis/trans = 1:2 to 1:3). Thus, [Dmt(1)]EM-2 analogues with hydrophobic C-terminal extensions provide model compounds with potent mu-opioid receptor bioactivity and dual functional agonism.

  DOI：

  10.1021/jm030649p
• 作为产物：
  描述：

  phthaloyl-L-phenylalanyl chloride 在 一水合肼 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 12.0h， 生成 (S)-α-amino-N-(4-pyridyl)benzene propanamide
  参考文献：
  名称：

  Synthesis and analgesic activities of urea derivatives of α-amino-N-pyridyl benzene propanamide

  摘要：

  New urea L-phenyl alanine derivatives of 4-aminopyridine have been synthesized and evaluated for analgesic activity with the PBQ writhing test in mice and the Randall-Selitto test in rats. Potent oral activity (ID50 < 10 mg/kg) and good tolerance were found in alkyl, arylalkyl and carboxyalkyl urea derivatives. The analgesic activity was found to be totally dependent on the pyridine moiety and was at least partly inhibited by pretreatment with (alpha) methyltyrosine, as was the case for 4-aminopyridine. These compounds are therefore pharmacologically interesting as new analgesic derivatives of 4-aminopyridine. They have a higher oral activity and a better activity/tolerance profile.

  DOI：

  10.1016/0223-5234(94)90070-1

文献信息

• Chiral Primary Amine-Polyoxometalate Acid Hybrids as Asymmetric Recoverable Iminium-Based Catalysts
  作者：Jiuyuan Li、Xin Li、Pengxin Zhou、Long Zhang、Sanzhong Luo、Jin-Pei Cheng

  DOI：10.1002/ejoc.200900594

  日期：2009.9

  acid–base assembly of multidentate chiral primary amines and solid polyacids is presented. A suitable structurally distinctive C2-symmetric chiral primary amine (CPA) was identified in this study and the optimal CPA–POM hybrid obtained catalyzed the Diels–Alder cycloaddition of α-substituted acroleins in high yields and fair-to-high selectivity under aqueous conditions. The primary amine in the metal–organic-framework

  提出了一种通过多齿手性伯胺和固体多元酸的酸碱组装固定亚胺有机催化剂的新策略。在本研究中确定了一种合适的结构独特的 C2 对称手性伯胺 (CPA)，获得的最佳 CPA-POM 杂化物在水性条件下以高产率和公平到高的选择性催化 α-取代丙烯醛的 Diels-Alder 环加成反应. 类金属有机骨架 (MOF) 催化剂中的伯胺充当催化中心和多齿碱性中心，而磷钨酸则充当催化剂锚和活性和立体选择性调节剂的双重作用。此外，类 MOF 催化剂表现出高反应性和物理稳定性，因此可以回收和重复使用 6 次，而活性和选择性损失很小。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2014043019A1

  公开（公告）日：2014-03-20

  The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公式I所涵盖的化合物包括HIV蛋白酶抑制剂和其他可在体内代谢为HIV蛋白酶抑制剂的化合物。这些化合物及其药学上可接受的盐对于预防或治疗HIV感染以及预防、治疗或延迟艾滋病的发作非常有用。这些化合物及其盐可以作为药物组合物的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• HIV PROTEASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2895482A1

  公开（公告）日：2015-07-22
• AMINOPYRIDINE COMPOUNDS AND THEIR USES
  申请人：Hudson Michael J.

  公开号：US20140024621A1

  公开（公告）日：2014-01-23

  The invention generally relates to aminopyridines and methods of use thereof. In certain embodiments, the invention provides an aminopyridine or a pharmaceutically-acceptable salt thereof, in which the aminopyridine or the salt thereof includes a cleavable functional group that substantially prevents extra-hepatic hydrolysis.
• US5200408A
  申请人：——

  公开号：US5200408A

  公开（公告）日：1993-04-06